Tin, Gallium, Germanium, Indium, Or Tellurium Patents (Class 424/650)
  • Patent number: 9517198
    Abstract: Provided are methods of treating pain, including neuropathic pain, in human and veterinary individuals. These methods employ locally administrable pharmaceutical gallium compositions, including pharmaceutical gallium compositions suitable for administration to the skin and mucous membranes. The compositions comprise pharmaceutically acceptable gallium compounds, such as gallium maltolate or gallium nitrate, together with pharmaceutically acceptable carriers suitable for local administration, including those suitable for topical administration. The administration of such compositions provides relief from pain, itching, allodynia, hyperalgesia, and related symptoms.
    Type: Grant
    Filed: August 12, 2014
    Date of Patent: December 13, 2016
    Inventor: Lawrence R. Bernstein
  • Patent number: 9114067
    Abstract: Provided are methods of treating pain, including neuropathic pain, in human and veterinary individuals. These methods employ locally administrable pharmaceutical gallium compositions, including pharmaceutical gallium compositions suitable for administration to the skin and mucous membranes. The compositions comprise pharmaceutically acceptable gallium compounds, such as gallium maltolate or gallium nitrate, together with pharmaceutically acceptable carriers suitable for local administration, including those suitable for topical administration. The administration of such compositions provides relief from pain, itching, allodynia, hyperalgesia, and related symptoms.
    Type: Grant
    Filed: October 23, 2014
    Date of Patent: August 25, 2015
    Inventor: Lawrence Richard Bernstein
  • Patent number: 9078840
    Abstract: Disclosed herein are substantially transparent and colorless dental varnishes having improved fluoride release, transparency and color once coated.
    Type: Grant
    Filed: February 14, 2014
    Date of Patent: July 14, 2015
    Assignee: DENTSPLY International Inc.
    Inventors: Xin Huo, Thomas C. Simonton
  • Patent number: 9080213
    Abstract: A method of determining identity, purity and/or potency of chondrocytes in vitro includes a) isolating and, optionally, culturing chondrocytes from a biological sample, and b) determining gene expression of at least one marker in the chondrocytes selected from the group consisting of FLT-1, IL-1beta, BSP-2, and type I collagen.
    Type: Grant
    Filed: July 27, 2011
    Date of Patent: July 14, 2015
    Assignee: TETEC Tissue Engineering Technologies
    Inventors: Juergen Mollenhauer, Christoph Gaissmaier
  • Publication number: 20150110886
    Abstract: The present invention generally relates to methods of treating hypertension (HTN) in patients in need thereof wherein the patient optionally further suffers from chronic kidney disease (CKD) or Type II diabetes mellitus (T2DM). The invention also relates to methods of treating hyperkalemia in a patient in need thereof, wherein the patient suffers from CKD, T2DM or HTN and are optionally being treated with an effective amount of a renin-angiotensin-aldosterone system (RAAS) agent. The invention also relates to methods of treating kidney disease in a patient in need thereof, wherein the patient is optionally being treated with an effective amount of a renin-angiotensin-aldosterone system (RAAS) agent. The methods can comprise administering an effective amount of a potassium-binding agent to the patient to lower the patient's blood pressure and/or increase or stabilize the patient's kidney function.
    Type: Application
    Filed: December 23, 2014
    Publication date: April 23, 2015
    Inventors: Gerrit Klaerner, Lance Berman
  • Patent number: 9011933
    Abstract: A novel method for treating skin and mucosal membrane ailments caused by human papilloma viruses, which utilizes tellurium-containing compounds, is disclosed. Also disclosed are pharmaceutical compositions containing tellurium-containing compounds for treating such ailments.
    Type: Grant
    Filed: January 23, 2005
    Date of Patent: April 21, 2015
    Assignee: Biomas Ltd.
    Inventors: Benjamin Sredni, Michael Albeck
  • Patent number: 8974815
    Abstract: Electrospun biodegradable poly(ester-amide) fabric is especially suitable as a scaffold for tissue engineering and to incorporate drug for burn or wound healing treatment to accelerate healing, or to prevent tissue adhesion after surgery.
    Type: Grant
    Filed: February 12, 2009
    Date of Patent: March 10, 2015
    Assignee: Cornell University
    Inventors: Chih-Chang Chu, Lei Li, Patti Jo Lewis
  • Publication number: 20150064284
    Abstract: The present invention relates to methods for preventing or treating infectious diseases caused by extracellular microorganisms, such as bacteria and fungi, by systemically administering to a patient a compound containing gallium. The extracellular microorganisms targeted by the present methods include methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus faecalis (VRE), E. coli O157:H7, fluoroquinolone-resistant Salmonella typhi, and the like. Furthermore, in the present methods, gallium compounds can be co-administered with one or more conventional antimicrobial agents to treat infectious diseases with reduced risks of creating multi-drug resistant pathogens. The methods of the present invention is also applicable to those microorganisms, such as ulcer-causing Helicobacter pylori, complete eradication of which so far has been difficult to achieve.
    Type: Application
    Filed: November 2, 2014
    Publication date: March 5, 2015
    Applicant: MOUNT SINAI SCHOOL OF MEDICINE
    Inventors: Daniel P. Perl, Sharon Moalem
  • Publication number: 20150004235
    Abstract: The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and/or avoid potential entry of particles into the bloodstream of the patient. Also disclosed is a method for preparing high purity crystals of UZSi-9 exhibiting an enhanced level of potassium exchange capacity. These compositions are particularly useful in the therapeutic treatment of hyperkalemia.
    Type: Application
    Filed: July 1, 2014
    Publication date: January 1, 2015
    Inventors: Donald Jeffrey KEYSER, Alvaro F. Guillem
  • Publication number: 20140377359
    Abstract: The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and/or avoid potential entry of particles into the bloodstream of the patient. Also disclosed is a method for preparing high purity crystals of UZSi-9 exhibiting an enhanced level of potassium exchange capacity. These compositions are particularly useful in the therapeutic treatment of hyperkalemia.
    Type: Application
    Filed: July 1, 2014
    Publication date: December 25, 2014
    Inventors: Donald Jeffrey KEYSER, Alvaro F. Guillem
  • Patent number: 8895077
    Abstract: The present invention relates to methods for preventing or treating infectious diseases caused by extracellular microorganisms, such as bacteria and fungi, by systemically administering to a patient a compound containing gallium. The extracellular microorganisms targeted by the present methods include methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus faecalis (VRE), E. coli O157:H7, fluoroquinolone-resistant Salmonella typhi, and the like. Furthermore, in the present methods, gallium compounds can be co-administered with one or more conventional antimicrobial agents to treat infectious diseases with reduced risks of creating multi-drug resistant pathogens. The methods of the present invention is also applicable to those microorganisms, such as ulcer-causing Helicobacter pylori, complete eradication of which so far has been difficult to achieve.
    Type: Grant
    Filed: March 28, 2008
    Date of Patent: November 25, 2014
    Assignee: Mount Sinai School of Medicine
    Inventors: Daniel P. Perl, Sharon Moalem
  • Patent number: 8871246
    Abstract: Provided are methods of treating pain, including neuropathic pain, in human and veterinary individuals. These methods employ locally administrable pharmaceutical gallium compositions, including pharmaceutical gallium compositions suitable for administration to the skin and mucous membranes. The compositions comprise pharmaceutically acceptable gallium compounds, such as gallium maltolate or gallium nitrate, together with pharmaceutically acceptable carriers suitable for local administration, including those suitable for topical administration. The administration of such compositions provides relief from pain, itching, allodynia, hyperalgesia, and related symptoms.
    Type: Grant
    Filed: August 6, 2013
    Date of Patent: October 28, 2014
    Inventor: Lawrence Richard Bernstein
  • Publication number: 20140302175
    Abstract: The present invention relates to novel methods of using microporous zirconium silicate to reduce the risk of hyperkalemia and to lower aldosterone levels in the treatment of chronic kidney disease and/or chronic heart disease with therapies comprising diuretics. The invention provides a safe way to reduce the risk of hyperkalemia and to lower aldosterone. The invention also relates to treatment of other conditions that can occur either alone or in connection with hyperkalemia, chronic kidney disease, and/or chronic heart disease.
    Type: Application
    Filed: April 3, 2014
    Publication date: October 9, 2014
    Applicant: ZS Pharma, Inc.
    Inventors: Donald Jeffrey KEYSER, Alvaro F. GUILLEM
  • Patent number: 8852561
    Abstract: Fluoride varnish compositions for temporary application and adhesion to a person's teeth. The composition includes a carrier comprising a resin and an adhesion promoting agent comprising an alkyl phosphoric acid. A fluoride ion source (e.g., a fluoride salt such as sodium fluoride) is dispersed within the carrier so as to provide biologically available fluoride ions to the tooth tissue being treated. The composition adheres only temporarily to tooth tissue (e.g., for a period of at least about 4 minutes, but not more than about 1 year), after which the composition spontaneously wears away as a natural result of the action of the tongue, saliva and/or other factors.
    Type: Grant
    Filed: February 7, 2013
    Date of Patent: October 7, 2014
    Assignee: Ultradent Products, Inc.
    Inventors: Jeff A. Wagner, Andy T. Kawamoto
  • Publication number: 20140271528
    Abstract: Provided herein are pre-formulations forming a biocompatible hydrogel polymer comprising at least one nucleophilic compound or monomer unit, at least one electrophilic compound or monomer unit, and optionally a therapeutic agent and/or viscosity enhancer. In some embodiments, the biocompatible hydrogel polymer covers a wound in a mammal and adheres to the surrounding skin tissue. In other embodiments, the hydrogel polymer is delivered into a joint space to treat joint disease or navicular disease.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 18, 2014
    Applicant: Medicus Biosciences LLC
    Inventors: Syed H. ASKARI, Yeon S. CHOI, Paul YuJen WAN
  • Patent number: 8808750
    Abstract: The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and/or avoid potential entry of particles into the bloodstream of the patient. Also disclosed is a method for preparing high purity crystals of UZSi-9 exhibiting an enhanced level of potassium exchange capacity. These compositions are particularly useful in the therapeutic treatment of hyperkalemia.
    Type: Grant
    Filed: September 25, 2013
    Date of Patent: August 19, 2014
    Assignee: ZS Pharma, Inc.
    Inventors: Donald Jeffrey Keyser, Alvaro F. Guillem
  • Patent number: 8802152
    Abstract: The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and/or avoid potential entry of particles into the bloodstream of the patient. Also disclosed is a method for preparing high purity crystals of UZSi-9 exhibiting an enhanced level of potassium exchange capacity. These compositions are particularly useful in the therapeutic treatment of hyperkalemia.
    Type: Grant
    Filed: February 10, 2012
    Date of Patent: August 12, 2014
    Assignee: ZS Pharma, Inc.
    Inventors: Donald Jeffrey Keyser, Alvaro F. Guillem
  • Publication number: 20140193521
    Abstract: This invention relates to drug delivery systems and methods of preventing respiratory bacterial infection in a foal of a mare. This invention relates to the reduction of transmission from the mare to the foal of bacteria though contaminated matter in the foal's environment.
    Type: Application
    Filed: August 10, 2012
    Publication date: July 10, 2014
    Inventor: Benjamin R. Buchanan
  • Publication number: 20140193520
    Abstract: The present invention provides methods for treating or preventing diseases and disorders caused by iron-dependent pathogenic microorganisms, such as bacteria, fungi, and parasites, by applying a gallium compound to an affected area. In particular, the present invention provides methods for treating or preventing dental caries, vaginal infections, skin infections, and so forth. Gallium compounds can be formulated as toothpaste, mouthwash, cream, ointment, gel, solution, eye drops, suppository, and the like. Furthermore, the invention provides methods for controlling microbial growth on environmental surfaces, including those of toothbrush, denture, dental retainer, contact lens, catheter, food stuff, and so forth. In addition, the present invention provides animal feeds which contain gallium compounds that promote the animal growth and prevent the animals from infections as well as protect consumers from post processing infections.
    Type: Application
    Filed: March 13, 2014
    Publication date: July 10, 2014
    Applicant: Mount Sinai School of Medicine
    Inventors: Daniel P. Perl, Sharon Moalem
  • Patent number: 8753561
    Abstract: Methods for processing substrate surfaces comprising metallic nanoparticles are disclosed. The methods involve providing a substrate surface comprising metallic nanoparticles, and exposing the substrate surface to a plasma.
    Type: Grant
    Filed: June 20, 2008
    Date of Patent: June 17, 2014
    Assignees: Baxter International Inc., Baxter Healthcare SA
    Inventors: Yann-Per Lee, John-Bruce D. Green, Jeffrey Bloss, Ozlem Yardimci
  • Patent number: 8703166
    Abstract: Antimicrobial and algaecidal products are disclosed. In general, the antimicrobial or algaecidal products can be adhered to structural components of buildings and include particles that, when combined with water, produce a solution that is toxic to organisms such as algae. The products provide an algaecidal wash as water percolates on, or through the product, and can prevent or control growth of unsightly algae and other microbes.
    Type: Grant
    Filed: January 20, 2011
    Date of Patent: April 22, 2014
    Inventor: John Flynn
  • Patent number: 8703211
    Abstract: The invention relates to the treatment and prophylaxis of cancer. In particular, the invention relates to a pharmaceutical agent comprising strontium, amino acid(s) and mineral element(s), and its use in the preparation of an agent useful for the treatment and prophylaxis of cancer. The invention also relates to a method for treatment and prophylaxis of cancer.
    Type: Grant
    Filed: November 30, 2009
    Date of Patent: April 22, 2014
    Assignee: Oy Neurofood AB
    Inventor: Thomas Tallberg
  • Publication number: 20140099350
    Abstract: The present invention relates to micro-sized particles having anti-biocontaminant properties. Each particle is comprised of a central metal core, or support structure, (for example, alumina oxide) and has on its surface, one or more anti-biocontaminant metals and at least one redox agent.
    Type: Application
    Filed: March 26, 2013
    Publication date: April 10, 2014
    Inventor: Dynamic Adsorbents, Inc.
  • Patent number: 8691288
    Abstract: Chronic rhinosinusitis and other bacterial sinus conditions may be treated by applying a solvating system containing a surfactant to a bacterial biofilm in a nasal or sinus cavity, disrupting the biofilm, and applying a protective layer of a polymeric film-forming medical sealant.
    Type: Grant
    Filed: July 13, 2011
    Date of Patent: April 8, 2014
    Assignee: Medtronic, Inc.
    Inventor: Matthew F. Myntti
  • Patent number: 8652509
    Abstract: A pharmaceutical composition and method for topical wound treatment by topical treatment with gallium salts, preferably gallium nitrate. In a preferred embodiment, the gallium nitrate is in an aqueous form without coagulation inhibitors such as citrate. The aqueous gallium salt formulation may be administered by a variety of methods including spraying, topical lotions, topical foams, and/or bandages containing or packaged with breakable ampoules of aqueous gallium salt formulations, and liquid bandage formulations. The aqueous gallium salt formulation may additionally contain other active and inactive ingredients, such as viscosity modifying agents, foaming agents, antiseptics, antibiotics, enzymes, fibrinogen, fibrin, polymers and growth factors.
    Type: Grant
    Filed: October 24, 2010
    Date of Patent: February 18, 2014
    Inventor: Moshe Rogosnitzky
  • Publication number: 20140044685
    Abstract: Nutritional compositions for maximizing muscle protein synthesis while minimizing the catabolism of muscle proteins and methods of using same are provided. In this manner, the nutritional compositions may provide for retention of lean body mass, which helps to avoid loss of independence and functionality, as well as to improve quality of life especially in the elderly at risk of sarcopenia and frailty. The nutritional compositions include ?-hydroxyisocaproic acid and citrulline. The composition may include other functional ingredients such as, but not limited to whey protein including whey protein micelles, prebiotic fibers, ?-keto-glutarate, eicosapentaenoic acid, L-carnitine, nucleotides, and amino acids. Methods of administering such nutritional products to individuals in need of same are also provided.
    Type: Application
    Filed: April 18, 2012
    Publication date: February 13, 2014
    Applicant: NESTEC S.A.
    Inventors: Norman Alan Greenberg, Denis Breuille, Zamzam Kabiry (Fariba) Roughead, Doug Bolster, Jennifer Mager
  • Publication number: 20140030241
    Abstract: Nutritional compositions having dietary nucleotides, ?-3 fatty acids and citrulline are provided. The nutritional compositions may be formulated to improve T cell function, increase arginine availability in vivo, regulate myeloid-derived suppressor cells (“MDSC”), and decrease the risk and/or severity of infection after surgery or trauma. Methods of making, using and administering such nutritional compositions to individuals in need of same are also provided. Methods for modulating the affects of MDSC's are also provided.
    Type: Application
    Filed: March 15, 2012
    Publication date: January 30, 2014
    Applicant: NESTEC S.A.
    Inventor: Norman Alan Greenberg
  • Patent number: 8637090
    Abstract: A method and composition for treatment of bacterial infections caused by gram negative or gram positive bacteria such as Staphylococcus aureus, Rhodococcus equi, Mycobacterium tuberculosis, Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Pseudomonas aeruginosa, Haemophilus influenzae, Proteus mirabilis, Enterobacter species, Serratia marcescens as well as those caused by Burkholderia cepacia, Stenotrophomonas maltophilia, Alcaligenes xylosoxidans, and multidrug resistant Pseudomonas aeruginosa, using a formulation containing gallium (III), in a pharmaceutically acceptable salt or complex thereof.
    Type: Grant
    Filed: May 4, 2010
    Date of Patent: January 28, 2014
    Assignee: Aridis Pharmaceuticals
    Inventors: Satoshi Ohtake, Vu Truong-Le, David Lechuga-Ballesteros, Luisa Yee, Binh V Pham, Russell Martin, Atul Saxena
  • Publication number: 20140004168
    Abstract: A biocidal glass composition for use in roofing applications can include glass doped with at least one biocidal agent that includes about 0.01 wt. % to about 50 wt. % of a total weight % of the biocidal glass composition. The biocidal glass composition can be included in a coating on a base particle of a roofing granule. Further included is a process of forming the roofing granule.
    Type: Application
    Filed: March 15, 2013
    Publication date: January 2, 2014
    Inventors: Pierre-Olivier Petit, Keith C. Hong, Gregory F. Jacobs, Kamila Plevacova
  • Publication number: 20130323297
    Abstract: Provided are methods of treating pain, including neuropathic pain, in human and veterinary individuals. These methods employ locally administrable pharmaceutical gallium compositions, including pharmaceutical gallium compositions suitable for administration to the skin and mucous membranes. The compositions comprise pharmaceutically acceptable gallium compounds, such as gallium maltolate or gallium nitrate, together with pharmaceutically acceptable carriers suitable for local administration, including those suitable for topical administration. The administration of such compositions provides relief from pain, itching, allodynia, hyperalgesia, and related symptoms.
    Type: Application
    Filed: August 6, 2013
    Publication date: December 5, 2013
    Inventor: Lawrence Richard Bernstein
  • Publication number: 20130302425
    Abstract: A method for the selection of pharmaceutically acceptable excipients that allow for the production of highly dispersible powders produced by spray drying.
    Type: Application
    Filed: November 18, 2010
    Publication date: November 14, 2013
    Applicant: Aridis Pharmaceuticals
    Inventors: Satoshi Ohtake, Atul Saxena, Vu Truong-Le
  • Publication number: 20130266629
    Abstract: A medical device intended for contact with living tissue comprises a substrate having a surface, which surface comprises a layer comprising one or more compound(s)) of at least one non-toxic post-transition metal, such as a gallium or bismuth compound. A layer comprising a compound of a non-toxic post-transition metal has been shown to inhibit biofilm formation on the surface of the medical device, which may reduce the risk for infection e.g. around a dental implant. A method of producing the medical device comprises: a) providing a substrate having a surface; and applying a compound of a non-toxic post-transition metal onto said surface to form a layer, e.g. using a thin film deposition technique.
    Type: Application
    Filed: March 13, 2013
    Publication date: October 10, 2013
    Applicant: DENTSPLY INTERNATIONAL INC.
    Inventor: Anna ARVIDSSON
  • Patent number: 8545808
    Abstract: The subject invention relates to the compositions for radiolabeling Diethylenetriaminepentaacetic Acid (DTPA)-dextran with Technetium-99m and for stabilizing the DTPA-dextran Cold Kit. The composition contains Stannous Chloride ions to reduce 99mTc-pertechnetate, Ascorbic Acid to reduce stannic ions to stannous ions to maintain a reducing environment, ?,?-Trehalose to add bulk and to stabilize the lyophilized composition without interfering with the radiochemical yield, and Glycine to transchelate Technetium-99m under highly acidic conditions to facilitate radiolabeling DTPA-dextran with high radiochemical purity. In addition, the invention pertains to methods for making and using the compositions. The reconstitution of the lyophilized composition by 99mTc-pertechnetate, resulting in radiolabeled 99mTc-DTPA-dextran in a composition between pH 3 to 4.
    Type: Grant
    Filed: May 1, 2012
    Date of Patent: October 1, 2013
    Assignee: Navidea Biopharmaceuticals, Inc.
    Inventors: Gerald Ross Magneson, Richard Cushman Orahood
  • Publication number: 20130236521
    Abstract: The present disclosure is directed to method of treating a herpes virus. In one embodiment, the method includes adding an effective amount of stannous fluoride (SnF2) to a dosage form. The dosage form may be a scrim, a liquid (e.g., a nasal mist, an aerosol spray, a liquid eye drop, a liquid bandage, and the like), a mucoadhesive or a lip balm.
    Type: Application
    Filed: March 7, 2013
    Publication date: September 12, 2013
    Applicant: HERPX LLC
    Inventors: Thomas Blake, Thomas S. Parigian, David E. Walsh
  • Patent number: 8506990
    Abstract: Provided are methods of treating pain, including neuropathic pain, in human and veterinary individuals. These methods employ locally administrable pharmaceutical gallium compositions, including pharmaceutical gallium compositions suitable for administration to the skin and mucous membranes. The compositions comprise pharmaceutically acceptable gallium compounds, such as gallium maltolate or gallium nitrate, together with pharmaceutically acceptable carriers suitable for local administration, including those suitable for topical administration. The administration of such compositions provides relief from pain, itching, allodynia, hyperalgesia, and related symptoms.
    Type: Grant
    Filed: October 10, 2012
    Date of Patent: August 13, 2013
    Inventor: Lawrence Richard Bernstein
  • Publication number: 20130149391
    Abstract: Fluoride varnish compositions for temporary application and adhesion to a person's teeth. The composition includes a carrier comprising a resin and an adhesion promoting agent comprising an alkyl phosphoric acid. A fluoride ion source (e.g., a fluoride salt such as sodium fluoride) is dispersed within the carrier so as to provide biologically available fluoride ions to the tooth tissue being treated. The composition adheres only temporarily to tooth tissue (e.g., for a period of at least about 4 minutes, but not more than about 1 year), after which the composition spontaneously wears away as a natural result of the action of the tongue, saliva and/or other factors.
    Type: Application
    Filed: February 7, 2013
    Publication date: June 13, 2013
    Applicant: Ultradent Products, Inc.
    Inventor: Ultradent Products, Inc.
  • Publication number: 20130102953
    Abstract: The present invention relates to a novel photocatalyst comprising Nano mixed metal oxides of titanium, Indium and tin as a thin film with nano sized grains, method of its preparation and applications. The photocatalyst disclosed herein can be used in oxygenation of human/mammalian blood along with all other applications of photocatalysts. A photocatalytic oxygenator for the oxygenation derives oxygen from the water content of mammalian blood. The photocatalyst disclosed herein can also be used for effluent treatments along with all other applications associated with photocatalysts.
    Type: Application
    Filed: June 23, 2010
    Publication date: April 25, 2013
    Applicant: HCL TECHNOLOGIES LTD.
    Inventors: Aryasomayajula Subrahmanyam, Paul J Tangaraj Ramesh
  • Publication number: 20130084319
    Abstract: Novel antimicrobial compositions and coatings are disclosed. The antimicrobial compositions consist of mixtures of taurolidine and protamine, including protamine salts. The antimicrobial compositions are particularly useful in coatings for implantable medical devices. The antimicrobial compositions are effective against a broad spectrum of microbes.
    Type: Application
    Filed: September 29, 2011
    Publication date: April 4, 2013
    Inventors: Joerg Priewe, Xintian Ming
  • Publication number: 20130072899
    Abstract: Pharmaceutical formulations suitable for iontophoresis thereof that provide enhanced iontophoretic delivery of gallium to at least one body surface are described and methods for administering gallium to a body surface via iontophoresis. In one embodiment, the body surface is human skin.
    Type: Application
    Filed: November 16, 2012
    Publication date: March 21, 2013
    Applicant: Nitric BloTherapeutics, Inc.
    Inventor: Nitric BloTherapeutics, Inc.
  • Patent number: 8383163
    Abstract: Fluoride varnish compositions for temporary application and adhesion to a person's teeth. The composition includes a carrier comprising a resin and an adhesion promoting agent comprising an alkyl phosphoric acid. A fluoride ion source (e.g., a fluoride salt such as sodium fluoride) is dispersed within the carrier so as to provide biologically available fluoride ions to the tooth tissue being treated. The composition adheres only temporarily to tooth tissue (e.g., for a period of at least about 4 minutes, but not more than about 1 year), after which the composition spontaneously wears away as a natural result of the action of the tongue, saliva and/or other factors.
    Type: Grant
    Filed: December 19, 2008
    Date of Patent: February 26, 2013
    Assignee: Ultradent Products, Inc.
    Inventors: Jeff A. Wagner, Andy T. Kawamoto
  • Publication number: 20130045287
    Abstract: Disclosed is a method of treating concussion or other brain trauma in humans or other mammals by administering an effective dose of a gallium compound or gallium complex to the injured human or other mammal. The gallium compound may comprise, e.g., gallium nitrate, a docosahexaenonic acid salt of gallium with one to three of the gallium ligands being from docosahexaenonic acid, or other gallium compound or complex or combinations thereof. The gallium compound or complex may be administered orally, by spray, intravenously, subcutaneously, transdermally, intramuscularly, mucoadhesively or through oral or nasal inhalation. A transdermal patch containing the gallium compound may be applied after onset of the concussion or other brain trauma to permit rapid delivery of the compound through the skin. The gallium compound is preferably administered in an amount sufficient to maintain steady state blood concentrations. A preferred dosing is about 0.5 to about 20.0 mg/kg/day of body weight.
    Type: Application
    Filed: August 13, 2012
    Publication date: February 21, 2013
    Inventor: Jan M. Troup
  • Publication number: 20130045183
    Abstract: The present disclosure relates to non-acidic extracts or fractions selected from a Boswellia low polar gum resin extract fraction (BLPRE), a Boswellia volatile oil fraction (BVOIL), and a Boswellia oil fraction (BOIL) and their compositions. BLPRE, BOIL, and BVOIL are each derived from the gum resin of a Boswellia species. These compositions are useful for improving mental condition, enhancing brain functions such as cognition, memory, learning, communication and brain health, for treating impaired memory, and for preventing, control or treating memory and cognition related disorders/diseases. Additionally, BOIL, BVOIL, and mixtures of BOIL and BVOIL are useful for enhancing the bioavailability of a biological agent.
    Type: Application
    Filed: September 14, 2012
    Publication date: February 21, 2013
    Applicant: LAILA NUTRACEUTICALS
    Inventors: Ganga Raju GOKARAJU, Rama Raju GOKARAJU, Venkata Kanaka Ranga Raju GOKARAJU, Trimurtulu GOLAKOTI, Kiran BHUPATHIRAJU, Venkata Krishna Raju ALLURI
  • Publication number: 20130034595
    Abstract: Provided are methods of treating pain, including neuropathic pain, in human and veterinary individuals. These methods employ locally administrable pharmaceutical gallium compositions, including pharmaceutical gallium compositions suitable for administration to the skin and mucous membranes. The compositions comprise pharmaceutically acceptable gallium compounds, such as gallium maltolate or gallium nitrate, together with pharmaceutically acceptable carriers suitable for local administration, including those suitable for topical administration. The administration of such compositions provides relief from pain, itching, allodynia, hyperalgesia, and related symptoms.
    Type: Application
    Filed: October 10, 2012
    Publication date: February 7, 2013
    Inventor: Lawrence Richard Bernstein
  • Publication number: 20130034617
    Abstract: Provided are compositions and methods to treat liver cancer and related disorders in human or veterinary individuals. Primary liver cancers, including those metastatic to other parts of the body, as well as many cancers metastatic to the liver, can be treated. The treatments comprise the administration of pharmaceutically acceptable gallium compositions, including gallium maltolate. Routes of administration include, without limitation, oral, intravenous, intratumoral, and in association with chemoembolization.
    Type: Application
    Filed: October 10, 2012
    Publication date: February 7, 2013
    Inventor: Lawrence Richard Bernstein
  • Publication number: 20130004588
    Abstract: Compositions and methods for treating and/or preventing conditions such as diaper rash and atopic dermatitis are disclosed. The compositions and methods are particularly useful in the treatment and prevention of diaper rash and diaper dermatitis caused by the prolonged contact of human skin with body waste. The methods employ the topical application of a trypsin-inhibiting agent to the area in need of such treatment, or the area where prevention is desired. The trypsin-inhibiting agent is preferably a divalent cation.
    Type: Application
    Filed: June 28, 2011
    Publication date: January 3, 2013
    Inventors: Connie B. Lin, Euen Thomas Graham Ekman Gunn, Ya-Ping Hu, Neema Kulkarni, Mary Catherine Mack
  • Patent number: 8293268
    Abstract: Provided are methods of treating pain, including neuropathic pain, in human and veterinary individuals. These methods employ locally administrable pharmaceutical gallium compositions, including pharmaceutical gallium compositions suitable for administration to the skin and mucous membranes. The compositions comprise pharmaceutically acceptable gallium compounds, such as gallium maltolate or gallium nitrate, together with pharmaceutically acceptable carriers suitable for local administration, including those suitable for topical administration. The administration of such compositions provides relief from pain, itching, allodynia, hyperalgesia, and related symptoms.
    Type: Grant
    Filed: March 14, 2012
    Date of Patent: October 23, 2012
    Inventor: Lawrence Richard Bernstein
  • Publication number: 20120251629
    Abstract: The present invention relates to a method of treating a patient for a condition where blood flow to a tissue or organ is interrupted. This method involves administering to a patient with a hypoxic condition where blood flow to a tissue or organ is interrupted, or at risk thereof, a compound that reduces the rate of HIF-1? inactivation in cells affected by the condition, thereby treating the patient for the condition. Also disclosed is a method of treating a tumor in a patient. In addition, the present invention relates to methods of identifying compounds as candidate drugs for treatment of hypoxic conditions and for treating tumors in a subject.
    Type: Application
    Filed: October 8, 2010
    Publication date: October 4, 2012
    Applicant: UNIVERSITY OF ROCHESTER
    Inventor: Marc Halterman
  • Publication number: 20120251450
    Abstract: Of the many compositions and methods provided herein, one composition includes a nanoparticle having a first oxide of a first metal and a dopant that includes an ion or an atom of a second metal. A method includes a method comprising providing a plurality of nanoparticles comprising a first oxide of a first metal and a dopant that comprises an ion or an atom of a second metal; providing a diseased cell and a healthy cell; contacting the diseased cell and the healthy cell with the nanoparticle; and allowing the nanoparticle to preferentially associate with the diseased cell.
    Type: Application
    Filed: April 4, 2011
    Publication date: October 4, 2012
    Inventors: Alex Punnoose, Denise Wingett
  • Publication number: 20120237455
    Abstract: Described herein are compositions comprising a combination of extracts, and methods of preparing and using the same.
    Type: Application
    Filed: December 1, 2010
    Publication date: September 20, 2012
    Applicant: COLGATE-PALMOLIVE COMPANY
    Inventors: Harsh M. Trivedi, Elizabeth K. Gittins
  • Publication number: 20120213847
    Abstract: The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and/or avoid potential entry of particles into the bloodstream of the patient. Also disclosed is a method for preparing high purity crystals of UZSi-9 exhibiting an enhanced level of potassium exchange capacity. These compositions are particularly useful in the therapeutic treatment of hyperkalemia.
    Type: Application
    Filed: February 10, 2012
    Publication date: August 23, 2012
    Applicant: ZS Pharma, Inc.
    Inventors: Donald Jeffrey Keyser, Alavaro F. Guillem